TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05438147

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT-100 DiNaMo
Description: Active Treatment (Study App)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT-100 DiNaMo
Description: Active Treatment (Study App)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT-100 DiNaMo
Description: Active Treatment (Study App)
Study: NCT05676736

Intervention type: OTHER
Intervention: No intervention
Description: No intervention to be done for the group
Study: NCT05487768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG measurement
Description: EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~* Knee extension while sitting (10x left - right)~* Bipodal squatting (10x)~* Unipodal stance (5x30 seconds left-right)
Study: NCT05438147

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care-as-Usual
Description: Care-As-Usual control

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care-as-Usual
Description: Care-As-Usual control

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care-as-Usual
Description: Care-As-Usual control
Study: NCT05427058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Hypogastric Plexus Block
Description: this procedure uses a transdiscal approach at the level of the L5-S1 vertebrae by injecting 5 ml of 1% lidocaine + 10 ml of 96% alcohol and confirmed by C-arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ganglion Impar Block
Description: this procedure uses a trans-sacrococcygeal approach by injecting 4 ml of 1% lidocaine + 6 ml of 96% alcohol and confirmed by C-arm.
Study: NCT05487768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG measurement
Description: EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~* Knee extension while sitting (10x left - right)~* Bipodal squatting (10x)~* Unipodal stance (5x30 seconds left-right)
Study: NCT04813562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
Description: 18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
Study: NCT06074432

Intervention type: OTHER
Intervention: Emergency Colorectal Resection
Description: Patients underwent resection due to colorectal carcinoma in emergency surgery
Study: NCT05802901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal manipulation
Description: Spinal manipulation of the lumbar spine only to be performed in the spinal manipulation arm/group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling of the lumbar erector spinae, multifidus, and gluteus medius on the symptomatic side performed in the dry needling arm/group.
Study: NCT06554431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Driven Repetitive Artmaking
Description: Three (3) art kits which all use repetitive artmaking processes (e.g., materials for mandalas, stamp making kit, weaving kit)
Study: NCT04813562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
Description: 18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
Description: 60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
Description: 60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56
Description: 18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56
Description: 18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56
Description: 60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56
Description: 60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
Study: NCT05802901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal manipulation and dry needling
Description: The spinal manipulation and dry needling arm/group receive both spinal manipulation and dry needling as outlined in the other groups.
Study: NCT03676647

Intervention type: OTHER
Intervention: Diagnostic DNA Methylation Signature
Description: Undergo collection of tissue samples
Study: NCT06405451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment to improve trunk control and stability for 30 minutes, twice a day, and six times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment to improve trunk control and stability for 30 minutes, twice a day, and six times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Description: Respiratory muscle training will be conducted using the Threshold IMT-Philips inspiratory training device and the Threshold PEP expiratory training device, both from Respironics®. Participants will be comfortably seated in a chair with their feet on the ground, without back support, and with the trunk at a 90° angle to the hips. A conventional nasal clip will be used to prevent air leaks. During forced expiratory training, participants will use the ThresholdPEP® with a customized mouthpiece and perform forced expiration through the resistance device. Inspiratory muscle training will follow the same procedure using the Threshold IMT® (45).~Both inspiratory and expiratory trainings will be repeated 10-15 times, 5 sets for 20 minutes in one session, with a rest time of 30-60 seconds between each set.
Study: NCT05291052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 8 mg (for patient weight \< 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
Study: NCT05558904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04246762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab
Description: Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Tablets, 20 mg, oral
Study: NCT06092437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sodium guided diuretic algorithm
Description: Loop diuretics are administered intravenously as soon as possible after diagnosis of ADHF and continued 3dd until recompensation. Spot urine sodium is measured 2 hours after administration of the first in-hospital IV diuretic dose and repeated until the target of 100mmol/L is reached in the first 72 hours of admission (after which, UrNa will be measured once daily). When target is not met, the next dosage of loop diuretic is doubled (max 3dd 250mg furosemide) and thereafter, other diuretics (thiazide, MRA) are added. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Treatment with IV loop diuretics left to the discretion of the treating physician. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
Study: NCT04246762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Tablets, 100 mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin+ Vitamin K
Description: Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup, 2 mg/mL, oral
Study: NCT05022147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency-Only Stimulation
Description: Control condition, constant high-frequency DBS stimulation (130Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Frequency-Only Stimulation
Description: Experimental condition, constant low-frequency DBS stimulation (60 Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation
Description: Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 10 seconds for low, respectively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation
Description: Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 50 seconds for low, respectively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation
Description: Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 50 seconds for low, respectively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation
Description: Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 10 seconds for low, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFF Dopaminergic Medication
Description: All six device interventions will be performed in medication OFF state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON Dopaminergic Medication
Description: All six device interventions will be performed in medication ON state
Study: NCT05785494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narstaende.se
Description: Web-site with supportive information, videos and chat forum targeting family caregivers of patients with life-threatening illness.
Study: NCT06076382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasound guided colorectal ESD surgery
Description: The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. After water injection, the lesion was scanned and (1) the direction of gravity was determined. (2) fibrosis/infiltration under the mucosa, and the fibrosis was divided into F0 (no fibrosis), F1 (cold fibrosis), or F2 (severe fibrosis). (3) The lesion was divided into nine compartments. Mark submucosal fibrosis/infiltration sites, according to nine compartments. (4) Based on the results of endoscopic ultrasound scanning of the lesion, the surgeon draw up surgical approach and perform injection and dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the traditional colorectal ESD surgery
Description: The control group underwent injection and dissection directly.
Study: NCT06109831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1918
Description: SHR-1918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1918 placebo
Description: SHR-1918 placebo
Study: NCT05291052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years.
Study: NCT05563220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
Study: NCT05542160

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pumpkin seed extract (IRK-19)
Description: Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pumpkin seed extract (IRK-19)
Description: Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
Study: NCT05627323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHM-1101 CAR-T cells
Description: Administered via ICT/ICV dual delivery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHM-1101 CAR-T cells
Description: Administered via ICT/ICV dual delivery
Study: NCT05563220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib 250 mg or 300 mg once daily in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
Study: NCT06123312

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tri-modality biopsy
Description: When the lung nodule is visualized by ultrathin bronchoscope (3mm) with RP-EBUS, Tri-modality biopsy is performed.
Study: NCT06481319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infertility Patient Navigator
Description: Assistance with infertility evaluation including scheduling appointments
Study: NCT06225258

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Description: Patients, who received Xanthohumol (Chmiel-Xn-Active, SALUTIS Pharmacy, Poland) as adjunctive therapy to treatment recommended by Surviving Sepsis Campaign. Xanthohumol is administrated by the nosogastric tube three times a day \*every 8 hours) at the dose of 2 mg.\\/kg body weight for 10 days. The first dose of Xanthohumol is administrated within 4 hours after the admission to the ICU.
Study: NCT04756453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clip-traction
Description: A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
Study: NCT04821089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200
Description: Several different doses will be administrated in a dose-escalation manner. One single injection will be injected locally into several sites across the glabellar region.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IPN10200 Placebo
Description: One single injection of study intervention will be injected locally into several sites across the glabellar region.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dysport
Description: Single administration of study intervention in stage 1 / step 2 only
Study: NCT04990167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: Using Tiotropium as a single agent asthma controller medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: Using Tiotropium as a single agent asthma controller medication
Study: NCT06642077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml
Description: A total of 2 ampoules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml were injected into the sternotomy incision site and around the chest tubes of 30 patients in the experimental group. The total number and dose of opioids, the total number and dose of analgesics used to relieve the pain of the patients in the 24 hours after the injection of 2 ampules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml, and the total number and dose of analgesics were recorded, and the patients were interviewed face-to-face 24 hours later, and PoRI was recorded. No intervention was performed on 30 patients in the control group, and standard treatment and care continued to be applied to these patients.
Study: NCT06483334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: IV infusion at different dose levels
Study: NCT06429748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive Transcranial Magnetic Stimultion
Study: NCT04836520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390+anatrozole
Description: SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
Study: NCT06483334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: IV infusion at different dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: IV infusion at different dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: IV infusion at different dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV infusion
Study: NCT04883229

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Halo Neuroscience Neurostimulator
Description: Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks.
Study: NCT05824494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab 10mg/kg,every 3 weeks,IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
Study: NCT05019209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: House Dust Mite Allergen
Description: D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
Study: NCT06357780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: close-loop synchronization controller with spontaneous mode
Description: 30 minutes period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during NIV mode.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: 30 minutes period where the synchronization of pressure support of patient effort during NIV mode will be manually set.
Study: NCT05019209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen-free air
Description: No allergen added to room ventilation of allergen challenge chamber
Study: NCT06375512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ Vaccine (IN001)
Description: Formulation for injection